NCT03180567

Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of bleeding) or a low INR (with a risk of thrombosis)

Detailed description

The results of this project will benefit in (1) Identification of novel features or mutation types in warfarin resistance genomes. (2) To determine whether other polymorphisms in noncoding regions or their unique haplotype combinations contribute to the variability in the maintenance dose of warfarin, and (3)personalization of the drug and deciding the correct dose from the start.

Conditions

• Thrombosis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Genetic Mutations	By next generation sequencing

Timeline

• Start date: 2017-06-06
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2017-06-08
• Last updated: 2017-06-08

Locations

1 site across 1 country: Egypt